Oncoinvent
Mindre end 1K følgere
ONCIN
Oslo Børs
Biotechnology & Pharmaceuticals
Health Care
Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.
Læs mereMarkedsværdi
-
Aktieomsætning
-
Omsætning
23,04 mio.
EBIT %
-687,2 %
P/E
-
Udbytteafkast, %
-
Finanskalender
20.5
2026
Generalforsamling '26
27.8
2026
Delårsrapport Q2'26
Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Oncoinvent AS: Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies
Oncoinvent AS: BerGenBio and Oncoinvent - Last day of trading in the shares of Oncoinvent
Bliv en del af Inderes community
Gå ikke glip af noget - opret en konto og få alle de mulige fordele
Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer